Clinical data | |
---|---|
Trade names | Monopril |
AHFS/Drugs.com | Monograph |
MedlinePlus | a692020 |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | ~36% |
Protein binding | 87% (fosinoprilat) |
Metabolism | liver, GIT mucosa (to fosinoprilat) |
Elimination half-life | 12 hours (fosinoprilat) |
Excretion | kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C30H46NO7P |
Molar mass | 563.672 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Fosinopril is an angiotensin converting enzyme (ACE) inhibitor[2] used for the treatment of hypertension and some types of chronic heart failure. Fosinopril is the only phosphonate-containing ACE inhibitor marketed, by Bristol-Myers Squibb under the trade name Monopril. Fosinopril is a cascading pro-drug. The special niche for the medication that differentiates it from the other members of the ACE Inhibitor drug class is that was specifically developed for the use for patients with renal impairment. This was through manipulation of the metabolism and excretion, and is seen that fifty percent of the drug is hepatobiliary cleared, which can compensate for diminished renal clearance. The remaining fifty percent is excreted in urine. It does not need dose adjustment.
It was patented in 1980 and approved for medical use in 1991.[3]